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We have synthesized and characterized gold nanoparticles (spheres and rods) with optical extinction bands within the “optical
imaging window.” The intense plasmon resonant driven absorption and scattering peaks of these nanoparticles make them suitable
as contrast agents for optical imaging techniques. Further, we have conjugated these gold nanoparticles to a mouse monoclonal
antibody specific to HER2 overexpressing SKBR3 breast carcinoma cells. The bioconjugation protocol uses noncovalent modes of
binding based on a combination of electrostatic and hydrophobic interactions of the antibody and the gold surface. We discuss
various aspects of the synthesis and bioconjugation protocols and the characterization results of the functionalized nanoparticles.
Some proposed applications of these potential molecular probes in the field of biomedical imaging are also discussed.
Copyright © 2007 Raja Gopal Rayavarapu et al. This is an open access article distributed under the Creative Commons Attribution
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1. INTRODUCTION
Optical imaging encompasses a multitude of techniques for
the elucidation of morphology, molecular function, and
metabolism of tissue with the general objective of detecting,
diagnosing, staging, and treatment monitoring of disease.
Progression of disease is usually accompanied by changes in
physiology and pathology that are manifested as location-
specific changes in optical properties thereby providing con-
trast for optical imaging to study disease.
Optical imaging techniques span the range from surface
to bulk imaging systems with applications ranging from “op-
tical biopsies” to full human breast imaging with resolutions
that cover the microscopic to macroscopic. Some important
imaging techniques for superficial tissue imaging are confo-
cal microscopy [1], two-photon microscopy [2], and opti-
cal coherence tomography (OCT) [3]. Techniques that per-
mit subsurface to deep imaging are diffuse optical imaging
(DOT) [4] and photoacoustic imaging [5].
The interaction of visible and near-infrared (NIR) light
with tissue is dominated by
(a) absorption processes which are due to the presence
of various chromophores such as hemoglobin, oxy-
hemoglobin, melanin, water, and lipids [6];
(b) scattering processes due to the cell membrane and cell
structures such as the nucleus, mitochondria, lyso-
somes [6].
Penetration of light in tissue is dependent on the extent
of the two processes above and is low in the high-energy vis-
ible region of the spectrum. This is due to high absorption
by hemoglobin and severe light scattering. In the wavelength
regime between 600 nm and 1100 nm, absorption and scat-
tering losses are minimal permitting high-light penetration.
This is the so-called “optical imaging window” which is ex-
ploited for deep imaging in tissue [7].
The sensitivity and specificity of optical imaging tech-
niques to visualize a pathological disorder are governed by
contrast: the ability of the disease to differentially scatter or
absorb light compared with nonpathological tissue and back-
ground noise. This native or endogenous contrast may not be
sufficient and in any case, the interactions of light with tissue
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are not disease-specific. Therefore, there is a role for exoge-
nously administered contrast enhancing agents which have
affinity for the disease site through biochemical interactions,
providing not only sensitive but also disease-specific signals.
Contrast agents for optical imaging thus far have near-
infrared dyes based on cyanine dyes [8] such as Indocyanine
Green [9], but in the last few years, gold nanoparticles [10–
12] have emerged as prime candidates due to their unusual
optical properties and inherent biocompatibility.
Gold metal nanoparticles (NPs) exhibit narrow and in-
tense absorption and scattering bands due to the phe-
nomenon of plasmon resonance. This occurs at the reso-
nance condition of the collective oscillation that the conduc-
tion electrons experience in an electromagnetic field of the
appropriate wavelength [13]. The plasmon resonant condi-
tion of gold NPs depends upon their size, shape, structure
(solid or hollow), and upon the refractive index of the em-
bedding medium. Spherical gold nanoparticles have a single
plasmon resonant extinction peak at around 520 nm, which
does not shift extensively with changes in size and refractive-
index of the surrounding medium. This is a wavelength at
which light penetration in tissue is poor due to strong scatter-
ing and absorption by hemoglobin, and gold nanospheres are
not useful in contrast enhancement for deep tissue imaging.
Rod-shaped NPs exhibit two plasmon resonances due to
oscillation of the conduction electrons along the short axis as
well as along the long axis of the particles. The former plas-
mon band is called the transverse resonance and the latter the
longitudinal resonance. While the transverse plasmon band
occurs in the neighborhood of 520 nm, the longitudinal band
is red-shifted. The extent of the red-shift depends on the as-
pect ratio of the nanorod; the higher the aspect ratio, the fur-
ther the shift. Thus by tailoring the length and/or width of
these particles, their extinction peaks may be made to cover
the low-energy visible to infrared wavelength regions.
The intense scattering and absorption of light, that oc-
curs under the plasmon resonant condition coupled with the
ability to tune the resonance into the near-infrared (NIR)
by manipulating the aspect ratio, make gold nanorods ex-
tremely attractive as contrast agents for optical imaging tech-
niques. Further, gold-protein chemistry is well developed
and several bioconjugation protocols are available in the lit-
erature, which allows the combination of the targeting func-
tionality of antibodies with such gold NPs. The inertness and
biocompatibility of gold in general hold promise the use of
gold NPs for in vivo imaging applications.
Gold NPs can be synthesized using wet chemical meth-
ods which are based on the reduction of gold salts by
reagents such as sodium borohydride and ascorbic acid.
Seed-mediated methods dominate wet chemical synthesis
routes. These involve the reduction of gold using weak
reducing agents onto small nanospheres of gold as seed,
in the presence of shape-directing surfactants usually cetyl
trimethylammonium bromide (CTAB). These methods may
be distinguished into those that use silver ion assistance in
growth solutions and those that do not.
Murphy and coworkers described the three-step growth
protocol [14, 15], where medium to high aspect ratio
nanorods could be synthesized, without the use of silver ni-
trate. Seed particles are generated by reducing gold salt us-
ing sodium borohydride in the presence of sodium citrate.
The spheres are coated with a layer of negatively charged
citrate ions that maintain colloid stability against aggrega-
tion by electrostatic repulsion. These spheres seed a growth
solution comprising gold salt, CTAB, and ascorbic acid in
three steps thereby slowing down reduction. The mechanism
of nanorod formation by this method is not yet fully un-
derstood. Murphy et al. [15] proposed that the polar CTA+
head group of the surfactant binds with greater preference
to certain crystallographic faces thereby passivating them to
the deposition of gold. The other faces, on the other hand,
would be exposed for gold to be reduced on, thereby pro-
ducing anisotropic growth into rods.
The methods using silver nitrate in the growth solu-
tions were proposed by Jana et al. [16], but modified by
Nikoobakht and El-Sayed [17] to achieve spectacular yields
of nanorods with excellent monodispersity. Importantly,
they also showed that changing the quantity of Ag+ ions in
the growth solution allows for fine-tuning of the aspect ratios
of the nanorods. The mechanism at work in this protocol has
been debated in the recent past. One mechanism postulates
CTAB as a soft template which elongates on addition of Ag+
ions which occupy regions between the CTA+ head groups to
reduce the repulsion between the head groups [17]. A second
mechanism invokes the CTAB passivation concept with ad-
ditional adsorption of silver bromide on facets slowing down
reduction and producing rods shorter than those made with-
out using Ag+ [18]. A third mechanism which has appeared
recently [19] proposes the underpotential deposition of Ag0
on certain faces, followed by CTAB binding, which serves to
stabilize the faces, and allows gold reduction on other faces
resulting in rod formation.
In this article, we present our experiences in synthesiz-
ing gold nanospheres and nanorods using slight modifica-
tions of the protocols discussed above. Our goal is to obtain
nanorods whose aspect ratios can be tuned to obtain plas-
mon peaks between 650 nm–850 nm. Next, we conjugate the
gold nanospheres and gold nanorods to the HER81 mono-
clonal antibody using electrostatic and hydrophobic interac-
tions. The conjugation does not use modifications of the bi-
layer charge of nanorods nor does it use any linkers. We dis-
cuss various aspects of these protocols and postulate a possi-
ble mechanism for the bioconjugation of the antibody with
the gold nanorods. We also discuss the feasibility of using
these molecular probes for contrast enhancement of photoa-
coustic cancer imaging using simulations.
2. EXPERIMENTAL SECTION:
MATERIALS AND METHODS
2.1. Gold nanorods using the silver-assisted single
surfactant growthmethod
As mentioned earlier, the seed-mediated protocol requires
the use of small gold nanospheres to seed growth solutions
with silver nitrate as per the protocol of Nikoobakht and El-
Sayed [17].
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Table 1: Mean aspect ratios, lengths, widths, and longitudinal plasmon peaks for nanorods synthesized using the silver-assisted growth
method.
Sample Volume of AgNO3 ( μL) Aspect ratio (R) Length (nm) Width (nm) LP band (nm)
1 50 2.3± 0.3 44.8± 4.1 19.8± 2.9 675
2 100 2.85± 0.6 45.1± 5.5 15.8± 3.1 764
3 150 3.0± 0.6 41.7± 3.9 13.9± 2.3 788
4 200 3.1± 0.5 52.0± 4.6 16.8± 2.8 831
5 250 3.6± 0.6 51.0± 4.4 14.1± 2.1 850
The following are the reagents used for the synthesis of
the gold seed and gold nanorods.
Tetrachloroauric acid (HAuCl4 · 3H2O) was purchased
from Acros Organics (Belgium), hexadecyltrimethylam-
monium bromide (CTAB > 99%), sodium borohydride
(NaBH4, 99%), and ascorbic acid (99%) from Aldrich (The
Netherlands) and silver nitrate (AgNO3, 99.8%) from Merck
(Germany). Prior to use, all glassware was cleaned with hy-
drofluoric acid (HF), further with aqua regia (HCl/HNO3)
and rinsed twice with deionized water.
Gold seed of 3.5 nm diameter
The synthesis was done using protocols of Nikoobakht and
El-Sayed [17] with slight modifications. A solution of CTAB
(5 mL; 0.2 M) was sonicated for 20 minutes at 40◦C in a wa-
ter bath. A solution of HAuCl4 · 3H2O (5 mL; 0.0005 M) was
added with continuous stirring under inert conditions (ni-
trogen environment). Then, an ice-cold aqueous solution of
NaBH4 (0.6 mL; 0.01 M) was added at once with vigorous
stirring for 1 minute. This seed solution (CTAB-capped) is
further used during growth stage of nanorods.
Gold nanorods of varying aspect ratios
Five identical conical flasks containing 10 mL of a growth so-
lution that consists of CTAB (5 mL; 0.2 M) and HAuCl4·
3H2O (5 mL; 0.001 M) were prepared. The color of the
growth solution is dark-yellow. AgNO3 (50, 100, 150, 200,
and 250 μL of 0.006 M) was added to the five identical growth
solution flasks in an amount that was chosen so as to yield
desired aspect ratios for the resulting nanorods. Following
this, the mild reducing agent ascorbic acid (70 μL; 0.1 M)
was added to each growth solution conical flask to give col-
orless solutions. Finally, 14 μL of preformed CTAB-capped
seed solution was added to each conical flask, and mixtures
were gently mixed. After 3 hours at 24◦C, the nanorod sus-
pension turned into a dark-blue solution with a brownish
opalescence. These solutions were concentrated by centrifug-
ing twice at 12000 g for 20 minutes which also enabled re-
moval of the excess unbound CTAB. The centrifuged gold
nanorods which are dispersed in water were stored at 4◦C.
2.2. Characterization of gold nanoparticles
Electron microscopy of the NPs was performed using a
CM 30 Philips transmission electron microscope (TEM) or
a Zeiss-1550 high-resolution scanning electron microscope
(HRSEM). Particle sizes were estimated using NI Vision
module (Labview, National Instruments) on the digital SEM
images with at least 250 particles considered in each case. Ex-
tinction spectra of NPs (and bioconjugated NPs) were mea-
sured using the Shimadzu PC3101 UV-Vis-NIR spectropho-
tometer.
The concentration of nanorods synthesized was esti-
mated using the relation A = cdε, where A is the measured
absorbance, c the concentration in moles (M), ε the molar
extinction coefficient ( M−1cm−1), and d the path length of
the cuvette used to record the spectra. The derived molar ex-
tinction coefficients can be compared with ε values from a re-
cent report, estimated for a range of aspect ratios of nanorods
by measuring the gold content in sols using inductively cou-
pled plasma (ICP) atomic emission spectroscopy [19].
2.3. Bioconjugation of HER81mAb to
gold nanoparticles
Conjugation was achieved using combination of electrostatic
and hydrophobic binding interactions. The particles chosen
for bioconjugation were 25 nm citrate-capped gold spheres
(Aurion, Wageningen, The Netherlands), and silver-assisted
surfactant mediated gold nanorods with aspect ratios of ap-
proximately 2.85 (see Table 1) with the longitudinal plasmon
peak at 764 nm. The anti-HER2 mouse monoclonal antibody
(mAb) (Immunicon, USA) was chosen as the targeting moi-
ety. The antibody designated as HER81 recognizes Human
EGF receptor 2, HER2. HER2, also called erbB2, is a member
of the epidermal growth factor receptor (EGFR) family and
is overexpressed in 20–40% of human breast cancers [20].
In general, for optimum conjugation, it is recommended
that the pH of the antibody and gold sol be maintained at or
slightly higher than the isoelectric point (pI) of the antibody
[21]. The isoelectric (pI) point of HER81 mAb was deter-
mined using the Pharmacia PhastSystem isoelectric focusing
(IEF). The pH of the antibody was adjusted with dialysis in
5mM sodium acetate buffer and the pH of the colloidal gold
was adjusted with 0.1 M KOH, to approximately 0.5 pH units
above this value.
Next, the minimum protecting amount of antibody to be
used for the conjugation is determined. This is the amount of
protein that is required to maintain colloidal stability of the
conjugated NPs upon addition of NaCl [21] as judged by col-
orimetric analysis; as long as the conjugated NPs turns blue,
particle aggregation takes place implying that the amount of
protein is not sufficient to stabilize the suspension. By trial,
different amounts of antibody are added to samples of the
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Figure 1: Optical extinction spectrum of preformed 8-minute-aged
CTAB-capped gold nanospheres as seed for nanorod synthesis.
gold sol, gently mixed, and allowed to stand at room tem-
perature for 2 minutes. Spectroscopic analysis reveals which
sample remains stable; the minimum amount of protein
added is then ascertained and is used for subsequent con-
jugation of the gold sol.
To block the free surfaces on the gold, 10% bovine serum
albumin (BSA) in dialyzed buffer (sodium acetate), main-
tained at the same pH as the antibody solution, is used. The
BSA was added to the conjugate to a final concentration of
1% and was allowed to incubate for 5 minutes. The resultant
was then centrifuged for 30 minutes at 12000 g to remove
excess protein and incompletely stabilized particles. The re-
sulting pellet is dispersed in phosphate buffered saline (PBS)
containing 1% BSA and stored at 4◦C.
2.4. Cell culture and cell-bioconjugate incubation
The HER2 positive mammary adenocarcinoma (SKBR3) cell
line was used as a positive cell line; Chinese hamster ovary
(CHO) cells were used as an HER2 negative cell line. The cells
were cultured in RPMI 1640 medium (Invitrogen) supple-
mented with glutamine, 10% FBS (Fetal Bovine Serum) with
antibiotics. Cells were maintained in an incubator at 37◦C
and 5% CO2.
The cells were detached from the tissue culture plate us-
ing trypsin. The cells were replated onto 12 mm glass cover
slips in a 6-well tissue culture plate, and allowed to grow for
2 days at 37◦C, 5% CO2. When the cells grew to 80% con-
fluence on the cover slips, the cells were rinsed with phos-
phate buffered saline (PBS) and fixed in 4% paraformalde-
hyde (PFA) for 15 minutes at room temperature.
2.5. Immunostaining and confocal microscopy
After fixation, immunostaining was performed on the cells.
The cells were incubated with 100 μL of conjugated gold
nanoparticles at a concentration of 9.7 × 1010 particles per
mL for 2 hours followed by silver enhancement performed
using a silver-staining kit (Aurion, Wageningen, The Nether-
lands).
Confocal microscopy reflection images of the cells on
cover slips were recorded on a Zeiss LSM 510 confocal laser
scanning microscope using a C-Apochromat 63 X/1.4 nu-
merical aperture (NA) water-immersion objective. An exci-
tation wavelength of 543 nm was chosen and reflection im-
ages recorded using a 500–550 nm bandpass filter. All images
were acquired with pinhole diameters of 178 μm. Care was
taken to ensure that the excitation intensity as well as detec-
tor and amplifier gains were maintained at the same values
for all images to facilitate comparison.
3. RESULTS
3.1. Synthesis of gold nanorods
We used seed particles within about 8 minutes of formation
in the subsequent growth phase. The optical extinction spec-
trum of 8-minute-aged seed is shown in Figure 1.
Figure 2 shows the extinction spectrum and HR-SEM
image of the nanorods synthesized using 50 μL AgNO3 in
the growth solution. The peak at 675 nm can be attributed
to longitudinal plasmon resonance and the peak in the vicin-
ity of 516.5 nm to transverse plasmon resonance.
Examination of the SEM image and determination of
the mean sizes confirm that the NPs produced consist of
monodisperse nanorods of aspect ratio of 2.3 ± 0.3, with a
small number of large spheres; the latter’s extinction peak co-
inciding with the transverse plasmon band of the nanorods.
Figure 3 shows the extinction spectrum and the SEM image
for the sample produced using 250 μL of silver nitrate. It is
seen that the longitudinal plasmon band is shifted to 850 nm.
Sizing from the SEM image yields an average aspect ratio of
3.6± 0.6. Figure 4 shows the size distribution of the 2 speci-
mens.
The values of the molar extinction coefficient for the 2
cases above are 3.3±0.3×109 and 5.5±0.3×109 M−1cm−1 ob-
tained by extrapolation of the data as reported in [19]. With
this, we arrive at the concentration of the nanorods with peak
at 675 nm as 4.3± 0.3 × 1011 NR/mL; for nanorods with the
peak at 850 nm as 1.3± 0.7× 1011 NR/mL.
Figure 5 shows the consolidated normalized extinction
spectra of 5 nanorod solutions, having identical growth so-
lutions with varying silver nitrate volumes. The spectra were
normalized to the peak at 516 nm, which is due to a combi-
nation of the transverse plasmon resonance of the nanorods
and the signature peak of gold nanospheres. It is seen that
with higher silver nitrate volumes the extent of red-shifting
increases [22]. The details of the observed changes in aspect
ratios and plasmon bands are presented in Table 1.
3.2. Bioconjugation of gold nanospheres
and gold nanorods
A signature for successful binding of protein to gold NPs is
a red-shifted and amplitude reduced plasmon band. Both
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Figure 2: Gold nanorods synthesized using 50 μL of silver nitrate in growth solution. (a) Optical extinction spectrum showing the transverse
plasmon peak at 516.5 nm and the longitudinal plasmon peak at 675 nm. The amplitude of the longitudinal plasmon peak is higher than
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Figure 3: Gold nanorods synthesized using 250 μL of silver nitrate in growth solution. (a) Optical extinction spectrum showing the transverse
plasmon peak at 516 nm and the longitudinal plasmon peak at 850 nm. (b) High-resolution scanning electron microscope (SEM) image.
these effects are due to the formation of the inhomogeneous
layer of protein on the gold particle surface that leads to the
modification of refractive index of the embedding medium.
Figure 6(a) shows the extinction spectrum of gold
nanospheres before and after incubation with HER81.
Figure 6(b) is the corresponding situation with gold
nanorods before and after incubation with the HER81 mAb.
In both cases, the characteristic red-shift in the extinction
peak of the plasmon bands is seen.
Not too much should be read into the amplitude changes
of the extinction spectra since centrifugation of the bioconju-
gate to remove unbound protein, redispersion in water, and
other procedures results in a change in the concentration of
the NPs used for spectroscopy.
Figure 7(a) show confocal reflectance image (on left) and
bright field image (on right) of the HER81 mAb/gold sphere
conjugates incubated with SKBR3 cells. As discussed in the
experimental section, silver enhancement was used by which
silver is reduced onto the gold particles forming large clus-
ters around 500 nm in size. This then enables visualization
under the microscope. The HER2 receptors are localized to
the cell membranes of SKBR3 cells. The high intensities in
both images at the cell membrane are then evidence of the
preservation of the functionality of the antibody and also il-
lustrate successful conjugation. The images in Figure 7(b),
which show the situation with the negative control using the
CHO cells, display no such accumulation of gold particles.
Also, adding nonantibody conjugated gold NPs to the SKBR3
cells did not result in accumulation of the nanorods, indicat-
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ing the specificity of the HER81 antibody-nanorod conjugate
(data not shown).
Figures 8(a) and 8(b) are the results of the corresponding
controls using the HER81 mAb/gold nanorods.
4. DISCUSSION
4.1. Gold nanorod synthesis
The end products of the seed-mediated growth protocols are
crucially dependent on the nature of the seed, upon their
size and upon the capping agents used. Additionally, the con-
stituents and their concentrations in the growth solution in-
fluence the outcome of the synthesis products. The addition
of silver ions in the growth solution and the use of preformed
CTAB stabilized seed in the protocol of Nikoobakht and
El-Sayed [17] produced not only a high yield of monodis-
perse nanorods but fine tunability of aspect ratios.
There are many unanswered questions regarding the
mechanism of formation of gold nanorods using the silver-
assisted protocol and this has been the topic of several studies
[15, 17–19]. Recent reports of Orendorff and Murphy [19],
and Liu and Guyot-Sionnest [23] provide some insights into
the mechanisms that could be involved in the synthesis. It is
postulated that silver ions are reduced by ascorbic acid even
though it is a weak reducing agent, by the phenomenon of
underpotential deposition (UPD). This is reduction of sil-
ver in monolayers on the growing gold nanorod surface at
a potential less than the standard reduction potential [19].
The deposition is not uniform on the gold surface but occurs
faster on the sidewalls compared with the end faces. Remark-
ably, the sidewalls in the case of nanorods produced with sil-
ver assistance using CTAB protected seed bear Au{110} faces,
while the end faces have Au{100} faces. This is in contrast to
the rods prepared by using citrate-capped seed without Ag+.
This faster passivation of the sidewalls is followed by CTAB
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Figure 5: Normalized extinction spectra of gold nanorods with in-
creasingly red-shifted longitudinal plasmon bands, synthesized us-
ing 50, 100, 150, 200, and 250 μL of silver nitrate in the growth so-
lution for curves 1–5, respectively. Normalization of the spectra is
done with respect to the transverse plasmon peak amplitudes.
binding possibly via bromide ions. This inhibits the reduc-
tion of gold, which deposits on the end faces. Ultimately,
the end faces are also stabilized preventing the formation of
very long nanorods. The model claims also to explain the in-
crease in aspect ratio of the nanorods produced with higher
concentration of silver ions used, by proposing that higher
UPD of silver monolayers occur on the sidewalls which one
assumes reducing the width of the nanorods thus increasing
the aspect ratios [19].
Indeed, we observe some phenomena that are consis-
tent with the above model. We are able to synthesize gold
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Figure 6: Extinction spectra before and after incubation of HER81 with (a) gold nanospheres, (b) gold nanorods. In both cases, a red shift
in plasmon band(s) occurs after incubation with the antibody signifying successful bioconjugation.
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Figure 7: Confocal reflectance images (left) and bright field images (right) of (a) SKBR3 cells incubated with silver-stained HER81/gold
sphere conjugates, (b) CHO cells under the same conditions. Care was taken to maintain the same acquisition parameters in both cases. The
silver-stained bioconjugates are detected at the cell membranes of SKBR3 cells where HER2 is localized. This indicates successful conjugation
and retention of functionality of the antibody after conjugation. No such accumulation of HER81/gold sphere conjugates is demonstrated
in HER2 negative CHO cells.
nanorods only up to an aspect ratio of 3.6, as shown in
Figure 3. Addition of higher volumes of silver nitrate pro-
duces no further increase in the aspect ratios of the particles.
These particles have an average length of 51 nm. This sup-
ports the idea that ultimately complete passivation of the en-
tire nanorod surface occurs preventing further gold deposi-
tion even though the reagents have not been exhausted. Fur-
ther, we observe that nanorods that are made with increasing
Ag+ volumes have smaller diameters with the lengths practi-
cally unchanged or only slightly increasing (see Table 1). The
above model can also explain this. It must be mentioned that
the model does not have an appealing explanation regarding
the ability to tune the aspect ratios so precisely by Ag+ vari-
ation. It is very likely that the model will have to undergo
refinements or even major changes before it is universally ac-
cepted.
4.2. Gold nanoparticle—antibody conjugation
The noncovalent conjugation of proteins to colloidal gold
is usually due to a combination of electrostatic and hy-
drophobic interactions. Citrate-capped gold NPs are nega-
tively charged due to a layer of negative citrate ions. Positively
charged amino groups of the antibody will be attracted to the
gold surface, and when the protein comes close enough for
binding, the hydrophobic pockets of the protein will make
contact and bind with the gold [24]. A general guideline to
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(a) (b)
Figure 8: Corresponding images as in Figure 7 for bioconjugates consisting of silver-stained HER81/gold nanorod conjugates incubated
with (a) SKBR3 cells and (b) CHO cells. Care was taken to maintain the same acquisition parameters in both cases. The bioconjugates are
accumulated at the cell membranes of SKBR3 cells where HER2 is localized. As expected, no such accumulation takes place in the case of
HER2 negative CHO cells.
Table 2: Important optical imaging techniques that utilize absorption and scattering contrasts in biology and medicine.
Technique Imaging depth Imaging resolution Mechanism Typical imaging applications
Confocal microscopy [1] 500 μm > 250 nm Scattering /absorption Tissue surfaces
Two-photon microscopy [2] 800 μm > 250 nm Absorption Tissue surfaces
Optical coherence
tomography [3]
2 mm 1 μm Scattering
Surfaces/subsurfaces
of tissue
Diffuse optical tomography [4] > 20 mm ≈ 10 % depth Scattering/absorption Small animal;
human breast and brain
Photoacoustic imaging [5] > 20 mm
<1 mm
(detector bandwidth limited)
Absorption
Subsurface to deep imaging;
small animal; human breast
optimize the bioconjugation is that the pH of the antibody
and the gold sol must be maintained at or slightly above the
isoelectric point of the antibody [24]. Following this, pro-
cedure for citrate-capped gold nanospheres with the HER81
antibody resulted in good bioconjugation as shown by the
spectroscopy and bioactivity studies (Figure 7).
With nanorods, the situation is more complex as com-
pared with nanospheres. The sidewalls of the nanorods
are expected to be stabilized with a bilayer of CTAB,
which imparts a positive charge to the gold. Huang
et al. [25] first changed the positively charged surface
to a negatively charged one by exposing the nanorods
to poly(styrenesulfonate) PSS polyelectrolyte solution. The
PSS-capped nanorods were then treated in the same way as in
Section 2.3 with the conjugation being done with anti-EGFR
monoclonal antibodies.
Zeta potentials of the gold nanorod solution as origi-
nally prepared were determined to be +55 mV. Centrifuga-
tion to remove the excess unbound CTAB and redispersion
of the rods in water saw a reduction in the zeta potential to
+7.5 mV, which also points to a low stability. We surmise that
inspite of the net positive charge, the unpassivated end faces
would be negatively charged due to the presence of AuCl−2
ions [21]. We therefore performed the same protocol (as in
Section 2.3) and found that the bioconjugation indeed was
achieved as demonstrated by the red-shifted extinction spec-
tra as seen in Figure 6. Further, confocal microscopy success-
fully detected the bioconjugates on the HER2 positive cell
line (Figure 8), indicating the success of the conjugation.
We believe that the mechanism of conjugation is the same
as that in the case of gold nanospheres that is electrostatic
and hydrophobic physisorption. It is also likely that at the
pH at which the antibody is maintained, the Fc fragment of
the antibody that is rich in positively charged amino acids
such as lysine will bind to the negatively charged chloride ion
layer on the exposed end faces of the rods. We intend to per-
form studies that will elucidate this aspect. Further, we will
perform the protocol of first capping the nanorods with PSS
for example, and then comparing the antigen binding affinity
constants of the bioconjugates from the two methods.
4.3. Potential contrast enhancing applications
The scattering and absorption bands of the synthesized
nanorods span the wavelength regime between 675–850 nm
that is of interest to optical imaging. This occupies the most
important part of the “optical imaging window” where light
penetration in tissue is high due to reduced scattering and
absorption coefficients. Optical imaging techniques (Table 2)
that rely on scattering and/or absorption contrast to de-
tect pathological tissue could benefit from the use of such
nanoparticles with or without targeting capability.
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Our goal is to employ these particles as contrast agents
for photoacoustic cancer imaging, which has been proposed
earlier by Oraevsky and coworkers [26, 27]. Photoacoustic
imaging relies on optical absorption for its signals. When
photons are absorbed, nonradiative de-excitation of the ab-
sorbed optical energy takes place with the release of local-
ized heat. The local thermal expansion that results produces
pressure transients [5]. When illuminated with pulsed laser
light, a tumor site by virtue of its higher absorption with
respect to the healthy background tissue, due to angiogen-
esis [28], will act as a source of bipolar photoacoustic pulses.
This ultrasound propagates with minimal distortion to the
surface where it is detected using appropriate wideband de-
tectors. The time-of-flight, amplitude, and peak-peak time of
the bipolar PA pulse possess information regarding the loca-
tion, absorption, and dimensions of the source, thereby per-
mitting a reconstruction of the tumor site [29, 30].
It is known that the NIR optical absorption contrast of
tumors versus healthy tissue, measured using optical mam-
mographic methods, is between 1.5 and 3. Clinical trials of
optical mammography are being conducted worldwide but
at present, it seems implausible that intrinsic contrast alone
will provide sufficient sensitivity and specificity, and targeted
contrast enhancement is likely to be required [31]. Since the
same contrast mechanism of optical absorption is operative
in photoacoustic imaging as well, a similar conclusion may
be anticipated.
An impression of the feasibility of using the nanorods
synthesized for contrast enhancement is now discussed. The
absorption cross-section of a nanorod at a wavelength, say
800 nm, is estimated using discrete dipole approximation
(DDSCAT) simulations [32, 33] as Cabs = 2.8 × 10−14 m2. A
typical average optical absorption coefficient for an invasive
ductal carcinoma is μa = 0.008 mm−1 at 800 nm. In order to
achieve contrast enhancement, a certain number density of
gold nanorods is required to exhibit higher absorption than
the intrinsic value and may be calculated as
ρNR ≥ μa
Cabs
. (1)
This gives ρNR = 2.8 × 108 NR/cm3. Further photoacoustic
signals can be enhanced by a thermal nonlinearity mecha-
nism to 3 orders of magnitude higher [34], then the mod-
ified number density of nanorods required is only ρNR =
2.8× 105 NR/cm3.
Published studies report that most tumour cell types ex-
press from 2×104 to 20×104 ErbB2 receptors/cell [12]. Let us
assume arbitrarily that 2×103 of these sites per cell are occu-
pied by conjugated nanorods. Further, if we assume that 1%
of cells at a tumor site overexpress HER2 results in a figure of
2× 106 cancer cells/cm3. This will then lead to an estimation
of the density of binding sites of the order of 109 cm−3. Com-
parison of ρNR and the estimated figure of density of binding
sites leads us to believe that contrast enhancement will be
possible.
We intend to test these molecular probes in small animal
photoacoustic imaging. Contrast enhancement with untar-
geted PEG-coated nanoparticles will be studied. Accumula-
tion of the contrast agent at the tumor site will depend on
enhanced permeation and retention (EPR). Active targeted
studies will follow, with conjugated nanoparticles adminis-
tered to the animal via the tail vein. In all studies, empha-
sis will be on ascertaining the sensitivity/efficacy of the tech-
nique with and without contrast agent.
5. CONCLUSIONS
We have synthesized gold nanorods with optical extinction
peaks in the region from 675–850 nm making these emi-
nently suited for scattering and absorption contrast enhance-
ments in optical imaging. We have performed bioconjuga-
tion of these nanorods with HER81 antibodies, which bind
with high efficiency to HER2 receptors expressed by SKBR3
breast carcinoma cells. We demonstrated in fixed cell stud-
ies that the targeting functionality of the antibody moiety re-
mains viable. However, it must be mentioned that the situa-
tion in vivo will be complex compared to the simplified situa-
tion in vitro. Other unresolved issues remain at present. One
of these is regarding toxicity and cellular uptake of these par-
ticles in vivo. Further, whether these molecular probes will be
able to extravasate into the tumor tissue through leaks in the
vasculature has not yet been studied. These are some lines of
research that we intend to follow in the near future.
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